These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12228116)

  • 1. Alosetron for irritable bowel syndrome.
    Lièvre M
    BMJ; 2002 Sep; 325(7364):555-6. PubMed ID: 12228116
    [No Abstract]   [Full Text] [Related]  

  • 2. Alosetron for irritable bowel syndrome. Senior vice president of GlaxoSmithKline responds.
    Palmer JB
    BMJ; 2003 Jan; 326(7379):51. PubMed ID: 12511473
    [No Abstract]   [Full Text] [Related]  

  • 3. Alosetron (Lotronex) is back: should I use it to treat my patients with irritable bowel syndrome?
    Shen B; Soffer EE
    Cleve Clin J Med; 2003 Jan; 70(1):64-5. PubMed ID: 12549728
    [No Abstract]   [Full Text] [Related]  

  • 4. Contemporary thoughts on the treatment of irritable bowel syndrome.
    Giaquinta D
    Manag Care Interface; 2002 Aug; 15(8):19-20, 22. PubMed ID: 12229060
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel medications for the irritable bowel syndrome: motility and sensation.
    Camilleri M
    J Pediatr Gastroenterol Nutr; 2001; 32 Suppl 1():S35-7. PubMed ID: 11321419
    [No Abstract]   [Full Text] [Related]  

  • 6. So what happened to alosetron?
    Hyams JS
    J Pediatr Gastroenterol Nutr; 2001 May; 32(5):513-4. PubMed ID: 11455947
    [No Abstract]   [Full Text] [Related]  

  • 7. New drugs to treat irritable bowel syndrome being tested.
    Mayo Clin Health Lett; 2000 Mar; 18(3):4. PubMed ID: 10734837
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
    Thumshirn M; Coulie B; Camilleri M; Zinsmeister AR; Burton DD; Van Dyke C
    Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alosetron for irritable bowel syndrome. Risks of using alosetron are still unknown.
    Palmer RH
    BMJ; 2003 Jan; 326(7379):51. PubMed ID: 12518769
    [No Abstract]   [Full Text] [Related]  

  • 10. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
    Olden K; DeGarmo RG; Jhingran P; Bagby B; Decker C; Markowitz M; Carter E; Bobbitt W; Dahdul A; DeCastro E; Gringeri L; Johanson J; Levinson L; Mula G; Poleynard G; Stoltz RR; Truesdale R; Young D;
    Am J Gastroenterol; 2002 Dec; 97(12):3139-46. PubMed ID: 12492201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA OK's two drugs for irritable bowel syndrome. The arsenal of IBS drugs is growing, but diagnosis is tricky.
    Horwitz BJ
    Health News; 2002 Oct; 8(10):1-2. PubMed ID: 12416480
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA draws patients into alosetron risk management.
    Miller JL
    Am J Health Syst Pharm; 2000 Oct; 57(19):1736. PubMed ID: 11030021
    [No Abstract]   [Full Text] [Related]  

  • 13. Serotonin receptor modulation in irritable bowel syndrome: one step forwards and one step backwards.
    Whorwell PJ
    Gut; 2001 May; 48(5):596-7. PubMed ID: 11302953
    [No Abstract]   [Full Text] [Related]  

  • 14. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
    Houghton LA; Foster JM; Whorwell PJ
    Aliment Pharmacol Ther; 2000 Jun; 14(6):775-82. PubMed ID: 10848662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irritable bowel syndrome: an overview of diagnosis and pharmacologic treatment.
    Olden KW
    Cleve Clin J Med; 2003 Jun; 70 Suppl 2():S3-7. PubMed ID: 12825862
    [No Abstract]   [Full Text] [Related]  

  • 16. Lotronex(tm): therapy for diarrhea predominant irritable bowel syndrome.
    McGahan L
    Issues Emerg Health Technol; 2000 Oct; (11):1-5. PubMed ID: 11902219
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.
    Mayer EA; Berman S; Derbyshire SW; Suyenobu B; Chang L; Fitzgerald L; Mandelkern M; Hamm L; Vogt B; Naliboff BD
    Aliment Pharmacol Ther; 2002 Jul; 16(7):1357-66. PubMed ID: 12144587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alosetron to return to market.
    Young D
    Am J Health Syst Pharm; 2002 Jul; 59(14):1323-4. PubMed ID: 12132555
    [No Abstract]   [Full Text] [Related]  

  • 19. Alosetron for irritable bowel syndrome.
    Barbehenn E; Lurie P; Wolfe SM
    Lancet; 2000 Dec; 356(9246):2009-10. PubMed ID: 11130544
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers.
    Clemens CH; Samsom M; Van Berge Henegouwen GP; Fabri M; Smout AJ
    Aliment Pharmacol Ther; 2002 May; 16(5):993-1002. PubMed ID: 11966509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.